23andMe Holding Co. (MEHCQ)
| Market Cap | 135.61M |
| Revenue (ttm) | 189.90M |
| Net Income (ttm) | -280.89M |
| Shares Out | 27.54M |
| EPS (ttm) | -10.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,593 |
| Average Volume | 180,971 |
| Open | 4.80 |
| Previous Close | 4.92 |
| Day's Range | 4.76 - 5.24 |
| 52-Week Range | 0.47 - 6.21 |
| Beta | 2.18 |
| RSI | 63.72 |
| Earnings Date | Jul 28, 2025 |
About 23andMe Holding Co.
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. It also operates Lemonaid telehealth platform to access affiliated licen... [Read more]
Financial Performance
In 2024, 23andMe Holding Co.'s revenue was $189.90 million, a decrease of -13.54% compared to the previous year's $219.64 million. Losses were -$280.89 million, -57.87% less than in 2023.
Financial StatementsNews
TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets
SAN FRANCISCO, July 14, 2025 (GLOBE NEWSWIRE) -- TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and founded and led by Anne Wojcicki, today announced that...
California fails to stop 23andMe founder from re-acquiring company
Genetic testing company 23andMe can proceed with a $305 million sale to the company's co-founder Anne Wojcicki after a U.S. bankruptcy judge rejected California's bid to delay the sale while the state...
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation
SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approva...
The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week's news.
UK Watchdogs Fine 23andMe $3.1M for Data Security Violations
The fine stems from the company's massive and "profoundly damaging" 2023 data breach.
UK Watchdogs Fines 23andMe $3.1 million For Data Security Violations
The fine stems from the massive and "profoundly damaging" 2023 data breach at the company.
23andMe fined millions by UK watchdog over 'profoundly damaging' cyber attack
The genetic testing company 23andMe is being fined £2.31m by the UK's privacy watchdog over their 2023 data breach that saw the personal information of seven million people stolen.
DNA testing firm 23andMe fined £2.3m by UK regulator for 2023 data hack
Information stolen from US company included details of 150,000 British residents including family trees
Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer
Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.
23andMe co-founder Anne Wojcicki regains control of bankrupt genetic testing company
Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.
Why is Anne Wojcicki regaining control of 23andMe and what it means for genomics firm
Anne Wojcicki, cofounder and former chief executive of 23andMe, is taking back control of the struggling genetic testing pioneer.
23andMe's founder wins bid to regain control of bankrupt DNA testing firm
Anne Wojcicki made $305m bid for firm, which has lost customers since declaring bankruptcy, with backing of Fortune 500 company
Former 23andMe CEO Anne Wojcicki wins bid for control of her former company, topping Regeneron
Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second auction.
Anne Wojcicki's nonprofit reaches deal to acquire 23andMe
Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to a nonprofit led by the company's co-founder and former CEO Anne Wojcicki.
Anne Wojcicki to buy back 23andMe and its data for $305 million
Anne Wojcicki's nonprofit will acquire substantially all of 23andMe's assets for $305 million, the company announced on Friday. 23andMe filed for for Chapter 11 bankruptcy protection in March.
23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm
23andMe filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data breachthat exposed sensitive genetic and personal information of milli...
23andMe's founder Anne Wojcicki wins bid for DNA testing firm
Anne Wojcicki is set to regain control of 23andMe after a nonprofit she controls topped Regeneron's bid for the DNA-testing company.
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
TTAM Commits to Comply with Company's Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data an...
Anne Wojcicki Wins Bidding for 23andMe
Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a higher bid.
States take legal action as 23andMe attempts to sell customer genetic information amid bankruptcy
Bankrupt 23andMe is facing a lawsuit over its plans to sell customer genetic information.
23andMe says 15% of customers asked to delete their genetic data since bankruptcy
23andMe's interim chief executive Joseph Selsavage told lawmakers on Tuesday that 1.9 million people, or about 15% of its customer base, have requested their genetic data be deleted from the company's...
Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research
Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology, and mo...
Rep. James Comer on 23andMe bankruptcy and data privacy
Rep. James Comer on Tuesday said he's concerned about the possibility that China could access 23andMe's genetic data, with the bankrupt company set to be purchased by pharma giant Regeneron. The House...
Rep. James Comer on 23andMe hearing: We want to know China won't end up with sensitive data
House Oversight Committee chairman Rep. James Comer (R-Ky.
Dozens of states sue to block the sale of 23andMe personal genetic data without customer consent
Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking to block the sale of personal genetic data by 23andMe without customer consent. The lawsuit comes...